Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.

MLA

Moghetti, P., et al. “Spironolactone, but Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist.” The Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 4, Apr. 1999, pp. 1250–54. EBSCOhost, https://doi.org/10.1210/jcem.84.4.5606.

APA

Moghetti, P., Castello, R., Zamberlan, N., Rossini, M., Gatti, D., Negri, C., Tosi, F., Muggeo, M., & Adami, S. (1999). Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. The Journal of Clinical Endocrinology and Metabolism, 84(4), 1250–1254. https://doi.org/10.1210/jcem.84.4.5606

Chicago

Moghetti, P, R Castello, N Zamberlan, M Rossini, D Gatti, C Negri, F Tosi, M Muggeo, and S Adami. 1999. “Spironolactone, but Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist.” The Journal of Clinical Endocrinology and Metabolism 84 (4): 1250–54. doi:10.1210/jcem.84.4.5606.